Why the timing of a knee OA diagnosis matters

Being told you have 'mild arthritis' and sent home without further context is a common experience — and a frustrating one. Mild on an X-ray does not mean early in biological terms, and early in biological terms does not mean unimportant. Knee osteoarthritis is a progressive process, not a single event, and the phase at which it is identified shapes almost everything about what can be done.

Tissue changes that drive long-term joint destruction — cartilage losing its biochemical integrity, subchondral bone beginning to remodel, low-grade inflammation taking hold — often begin years before pain becomes disabling or imaging looks dramatic. There is a window during this process, broadly the period before cartilage and bone reach structural exhaustion, when intervention can still alter the trajectory rather than simply manage the symptoms of an already settled outcome.

Once that window has passed, the goal of treatment shifts: from slowing or redirecting the disease to managing pain and eventually replacing the joint. Timing is not incidental to treatment — it determines what treatment can realistically deliver. The evidence for this is the subject of the rest of this article.

How joint damage gets ahead of symptoms

The Kellgren-Lawrence (KL) scale — the standard grading system applied to knee X-rays — measures structural change: joint space narrowing, osteophyte formation, and bone shape. What it cannot capture is biochemical deterioration. MRI studies in patients at low KL grades consistently identify advanced multi-tissue damage already present across cartilage, menisci, and bone marrow, damage the plain film simply does not resolve. The radiographic threshold and the biological threshold are not the same line.

Cartilage offers a narrower window still. Before any visible structural defect develops, the tissue's biochemical composition begins to change — a process that compositional MRI techniques such as T2 mapping, dGEMRIC, and T1ρ imaging can detect by measuring water content and collagen organisation rather than shape. At this pre-structural phase, damage may still be reversible; once a structural defect has formed, cartilage's regenerative capacity — constrained by its lack of blood supply — is effectively spent. Compositional MRI is not yet widely available in routine clinical settings, and no universally accepted diagnostic criteria exist for this stage, but the principle is central to the early-window argument: if detection waits for the X-ray to look abnormal, the reversible phase has already passed.

Beneath the cartilage, subchondral bone is among the first structures to show measurable change in OA. Cyst formation creates elevated mechanical stress that feeds back to accelerate articular surface breakdown — a process that can be well underway before a standard X-ray flags anything of concern.

An inflammatory process driven by the joint's innate immune system runs in parallel, sustaining and extending tissue destruction over time. In plain terms: early control of this inflammation can limit how far damage spreads; it cannot rebuild what has already been lost. A reassuring low-grade KL result, in other words, is not biological clearance.

The structural factors that make early OA progress faster

Not every early OA case follows the same trajectory. Three structural factors — the limited self-repair capacity of cartilage, meniscal integrity, and lower-limb alignment — go a long way towards explaining why some joints deteriorate quickly while others remain comparatively stable for years.

As a practical consequence of cartilage's constrained biology, defects above roughly 1 cm in size tend to enlarge over time rather than stabilise without intervention. Many patients reaching an early OA diagnosis already have defects at or approaching that threshold, which is one reason that 'mild' on an X-ray can still carry meaningful structural risk.

The meniscus is perhaps the most clinically underappreciated driver. Acting as a shock absorber and load distributor, it protects the articular surface with every step. The association between meniscal loss after meniscectomy and accelerated joint degeneration has been documented since at least 1923, and the Framingham study identified meniscus damage as a component of OA development. For patients who have had a previous meniscal procedure, this history is directly relevant to how quickly their joint may progress — and it underlines why meniscal preservation, where achievable, is regarded as a preventive act in its own right.

Alignment adds a mechanical multiplier. Varus stance, varus thrust during walking, and an elevated knee adduction moment all concentrate load on the medial compartment. Importantly, these are modifiable: gait retraining, bracing, and — where appropriate — surgical realignment can redistribute force while sufficient cartilage and bone remain to benefit from the change.

When all three factors coincide — limited repair capacity, reduced meniscal protection, and malalignment — progression tends to accelerate beyond what any single factor predicts alone. Identifying which combination is present shapes what early management can realistically target.

What treatment can achieve early versus late

Anti-TNF-α therapy provides the clearest available clinical evidence that the treatment window is real. In knee OA patients at Kellgren-Lawrence grade 2–3, the therapy produced significant improvements in WOMAC pain, stiffness, and function scores. Applied to end-stage disease, the same intervention showed no meaningful benefit. The difference is not about the drug; it is about what the joint still contains — enough viable tissue to respond.

A five-year prospective study of a cell-free nanostructured osteochondral scaffold in patients with KL grade 0–II disease — mean age 39 — produced stable improvements in IKDC scores at five years with a complication rate of 8.3%. The findings support the principle that structural salvage is achievable in early-stage joints. The study enrolled 22 patients, however; it represents early supporting signal, not a definitive evidence base.

The reversibility argument has a clear ceiling. Biochemical cartilage changes — detectable before visible structural defects form — represent the phase at which restoration may still be possible. Once structural defects are established and subchondral bone remodelling is advanced, the realistic treatment goal shifts from restoration to limiting further loss.

The DMOAD landscape reinforces this. No disease-modifying osteoarthritis drug has received regulatory approval. Multiple Phase II and III trials failed, with inadequate patient stratification by disease stage — treating end-stage joints as if they were early — identified as a contributing reason. The practical consequence is that non-pharmacological interventions in structurally preserved joints — load management, alignment correction, weight reduction, and biologics — remain the primary actionable tools available today. Current evidence that exercise slows structural OA progression is weak; its established value lies in symptom management and biomechanical function, which are meaningful goals in their own right.

Who is affected and what early-stage knee OA looks like

Roughly one in ten men and one in seven women may have early-stage knee OA — figures drawn from applying formal classification criteria to a Japanese general-population study. Those numbers should not be mapped directly onto a UK population, but they indicate the condition is common and that the majority of cases go unidentified at the early stage.

Part of the diagnostic gap traces back to how OA has historically been classified. The 1986 American College of Rheumatology criteria were built around established disease, not its earliest phases. It was not until a 2014 expert workshop in Tokyo that a first draft of specific early-OA criteria emerged, spanning patient-reported symptoms, clinical signs, and imaging findings. That framework remains provisional; no single definition has yet been universally adopted.

In practice, early-stage knee OA tends to present as aching during or after physical activity, stiffness that eases within twenty to thirty minutes of moving, occasional mild swelling after heavier use, and a reduced sense of confidence in the joint on slopes, stairs, or uneven ground. Constant rest pain and meaningful loss of movement range are features of more advanced disease; their absence does not mean the joint is structurally intact.

Symptoms and tissue change do not track each other reliably. A patient with modest discomfort may already have significant cartilage-level change, while someone with noticeable aching may have comparatively limited structural involvement. Recognised risk factors include prior meniscal or ligament injury, raised BMI, varus lower-limb alignment, female sex, and sustained repetitive loading — several of which are modifiable through targeted intervention.

When to seek assessment and what to expect

Activity-related knee pain that persists beyond six to eight weeks — particularly alongside any history of meniscal injury, varus alignment, or other recognised risk factors — is a reasonable threshold for seeking specialist review rather than continued watchful waiting.

A thorough early-OA evaluation goes further than a standard GP appointment. It covers a detailed clinical history, physical examination that includes alignment and gait assessment, and imaging. At early disease stages, MRI provides substantially more information than X-ray: low Kellgren-Lawrence grades on plain film can coexist with significant cartilage and meniscal change that only MRI resolves. The point of assessment at this stage is not to confirm end-stage disease but to catch the joint before that picture develops.

Seeking assessment is not about fast-tracking to treatment. It is about establishing a baseline, identifying which risk factors are modifiable, and building a management plan before the structural window narrows. For most patients, that plan begins with conservative care — physiotherapy, load management, and weight optimisation — which remain central even when biologic or procedural options are later considered.

The practical benefit of acting early is breadth of choice. Patients whose joints are structurally preserved have access to a wider range of interventions than those presenting at an advanced stage. Remaining in the part of the disease course where meaningful choices are still open is, for most patients, reason enough.

1. [1] Early knee OA definition – what do we know at this stage? An imaging perspective. (2023). https://doi.org/10.1177/1759720X231158204 https://doi.org/10.1177/1759720X231158204
2. [2] Cell-Free Osteochondral Scaffold for Focal Cartilage Defects in Early Knee OA: 5 Years' Follow-Up. (2019). https://doi.org/10.3390/jcm8111978 https://doi.org/10.3390/jcm8111978
3. [3] Drug repurposing for osteoarthritis disease modification in the early 21st century. (2025). https://doi.org/10.1080/03008207.2025.2538562 https://doi.org/10.1080/03008207.2025.2538562
4. [4] New Developments in Clinical Trials for OA: Are We Closer to Improving Pain Management and Disease Modification?. (2024). https://doi.org/10.33590/emj/uniy9778 https://doi.org/10.33590/emj/uniy9778